Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 3/20 | 0.58 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23686560 | 0.81 | TBXAS1 (0.50) | TBXAS1PRKCINAMPTBRD4CREBBP | |
| SCHEMBL24339261 | 0.79 | TBXAS1 (0.57) | TBXAS1PRKCINAMPTBRD4CREBBP | |
| SCHEMBL21037102 | 0.78 | TBXAS1 (0.50) | TBXAS1PRKCICNR1NAMPTBRD4 | |
| SCHEMBL25124500 | 0.75 | TBXAS1 (0.40) | TBXAS1PRKCINAMPTBRD4CREBBP | |
| SCHEMBL10974966 | 0.74 | TBXAS1 (0.67) | TBXAS1NAMPT | |
| SCHEMBL29304893 | 0.74 | TBXAS1 (0.57) | TBXAS1CNR1CNR2NAMPTLCK | |
| SCHEMBL26108096 | 0.72 | TBXAS1 (0.48) | TBXAS1NAMPT | |
| SCHEMBL12093717 | 0.72 | TBXAS1 (0.43) | TBXAS1PRKCINAMPTBRD4CREBBP | |
| SCHEMBL20689775 | 0.70 | TBXAS1 (0.40) | TBXAS1PRKCINAMPTBRD4CREBBP | |
| SCHEMBL14669955 | 0.69 | TBXAS1 (0.48) | TBXAS1PRKCINAMPTBRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | TBXAS1 1602/4885PRKCI 75/4885CNR1 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.